Market Cap 9.32M
Revenue (ttm) 3.00M
Net Income (ttm) 39.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1,326.33%
Debt to Equity Ratio 0.00
Volume 66,132
Avg Vol 1,241,507
Day's Range N/A - N/A
Shares Out 984,000.00
Stochastic %K 36%
Beta 1.12
Analysts Sell
Price Target $285.25

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices
Sector: Healthcare
Phone: 917 813 1828
Address:
360 Madison Avenue, 25th Floor, New York, United States
chuckjackson
chuckjackson Feb. 23 at 8:34 PM
$PAVM I'm trying to reconcile why pavm is relatively weak compared to lucd. The conversion of preferred shares and warrants is an eventuality. The total number of shares outstanding will be: 921k (current including options) 4.615M (conversion from preferred) 4.615M (from warrants) 1.5M (additional equity grants) --‐------------- 11.651M shares outstanding Based on today's price at $9.23, the market cap of pavm will be eventually $107.5M Their holdings in lucd are worth $44.485M (31M x 1.435) So pavm is trading at a premium compared to the value of their holdings in lucd. The main play we have in the near-term is for the stock to shoot up from the LCD because of the limited float. Is this the correct way to look at it?
1 · Reply
Ironbow
Ironbow Feb. 23 at 4:11 PM
$LUCD $PAVM Ignore Dip&hit Dave~ LPlates ~dmc4321 His three personalities are conflict again this morning 👇🏻
0 · Reply
dmc4321
dmc4321 Feb. 23 at 4:04 PM
$LUCD & $PAVM It is an OaksApollo post so we know its a lie and its a BIGGIE. He uses retail shareholders as his liquidity. He trades LUCD and when he says buy the dip he is selling into your liquidity. Just look at how many people LUCD would have to have recruited and trained to hit his projected numbers. How about another 50+ sales people and probably 100+ nurses as you need to figure in travel time etc. Can you imagine how difficult it would be to hire 100 what in effect are Travel Nurses? Do you know how impossible that would be and how expensive as their per diems are big $$.
0 · Reply
__ChartMenace
__ChartMenace Feb. 23 at 12:16 PM
0 · Reply
My_Lai_1968
My_Lai_1968 Feb. 23 at 7:10 AM
$PAVM Did PAVM have a Reverse Split within the past year or so? I used to follow it closely in the past. Thank you!
1 · Reply
DunnoT
DunnoT Feb. 21 at 1:01 PM
Nice potential short term long opportunity for $ATOM.X based on 2 similar events: [Ticker; End date] $QBTS 2024-12-05 $PAVM 2021-12-02 1) Break current high 2) Hit resistance at around +40% 3) Drop somewhere around previous high 4) Bounce and breakout previous resistance https://www.tradingview.com/chart/ATOM/kl9KaeBs-Similar-events-for-ATOM/
0 · Reply
LindaRice1041
LindaRice1041 Feb. 21 at 9:06 AM
$PAVM PAVmed develops medical devices. Commercial execution drives valuation. Balance sheet risk remains.
0 · Reply
chuckjackson
chuckjackson Feb. 20 at 5:56 PM
$PAVM why would shareholders vote to allow conversion of series D preferred shares to common shares?
0 · Reply
dmc4321
dmc4321 Feb. 20 at 5:34 PM
wow you are DUMBER THAN A ROCK. I said dont panic and attached the image showing it was an Annual Review, and then everybody else looked at my due diligence and said exactly what I said. It is all time stamped. As for $LUCD AND $PAVM I as you can read if you were not DUMBER THAN A ROCK " But if it (EsoGuard) truly is not covered and won't be covered it is just plain wrong, but LUCD will trade at 50 cents today and PAVM below $3 if it is truly NON COVERED" So to break it down into little pieces like you were a 6 year old. This is what I said. if EsoGuard is not covered that is a bad decision and is wrong. But IF CMS makes that bad decision that IMO is WRONG then the markets will react knowing that LUCD is BROKE in September and would be TWO More years MINIMUM away from approval (probably 3 to 4) by selling hard and 50 cents is probably generous. More like 30 cents. Likewise PAVM would immediaetly trade in the $2 to $3 range and soon be back in sub $1. do you understand now?
2 · Reply
dmc4321
dmc4321 Feb. 20 at 8:14 AM
$LUCD I was the ONLY poster to say 'DON'T PANIC' as all the rest of the PUMPERS were saying 'whats happening" It is all time stamped so if you think I am wrong all you have to do is show JUST ONE post from ANYONE timestamped BEFORE my 'DONT PANIC' post. You won't, because you can't.😇 As for $PAVM and $LUCD saying there is an arbitrage opportunity just shows your ignorance, STUPIDITY, and lack of accurate DUE DILIGENCE. So prove me wrong. I'll wait but I already know that i will hear 🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗from you.
2 · Reply
Latest News on PAVM
PAVmed Announces Reverse Stock Split

Dec 30, 2025, 9:01 AM EST - 7 weeks ago

PAVmed Announces Reverse Stock Split


PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 11:31 AM EST - 3 months ago

PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript


PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript

May 15, 2025, 1:58 PM EDT - 10 months ago

PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript


PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 11:08 AM EDT - 11 months ago

PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript


chuckjackson
chuckjackson Feb. 23 at 8:34 PM
$PAVM I'm trying to reconcile why pavm is relatively weak compared to lucd. The conversion of preferred shares and warrants is an eventuality. The total number of shares outstanding will be: 921k (current including options) 4.615M (conversion from preferred) 4.615M (from warrants) 1.5M (additional equity grants) --‐------------- 11.651M shares outstanding Based on today's price at $9.23, the market cap of pavm will be eventually $107.5M Their holdings in lucd are worth $44.485M (31M x 1.435) So pavm is trading at a premium compared to the value of their holdings in lucd. The main play we have in the near-term is for the stock to shoot up from the LCD because of the limited float. Is this the correct way to look at it?
1 · Reply
Ironbow
Ironbow Feb. 23 at 4:11 PM
$LUCD $PAVM Ignore Dip&hit Dave~ LPlates ~dmc4321 His three personalities are conflict again this morning 👇🏻
0 · Reply
dmc4321
dmc4321 Feb. 23 at 4:04 PM
$LUCD & $PAVM It is an OaksApollo post so we know its a lie and its a BIGGIE. He uses retail shareholders as his liquidity. He trades LUCD and when he says buy the dip he is selling into your liquidity. Just look at how many people LUCD would have to have recruited and trained to hit his projected numbers. How about another 50+ sales people and probably 100+ nurses as you need to figure in travel time etc. Can you imagine how difficult it would be to hire 100 what in effect are Travel Nurses? Do you know how impossible that would be and how expensive as their per diems are big $$.
0 · Reply
__ChartMenace
__ChartMenace Feb. 23 at 12:16 PM
0 · Reply
My_Lai_1968
My_Lai_1968 Feb. 23 at 7:10 AM
$PAVM Did PAVM have a Reverse Split within the past year or so? I used to follow it closely in the past. Thank you!
1 · Reply
DunnoT
DunnoT Feb. 21 at 1:01 PM
Nice potential short term long opportunity for $ATOM.X based on 2 similar events: [Ticker; End date] $QBTS 2024-12-05 $PAVM 2021-12-02 1) Break current high 2) Hit resistance at around +40% 3) Drop somewhere around previous high 4) Bounce and breakout previous resistance https://www.tradingview.com/chart/ATOM/kl9KaeBs-Similar-events-for-ATOM/
0 · Reply
LindaRice1041
LindaRice1041 Feb. 21 at 9:06 AM
$PAVM PAVmed develops medical devices. Commercial execution drives valuation. Balance sheet risk remains.
0 · Reply
chuckjackson
chuckjackson Feb. 20 at 5:56 PM
$PAVM why would shareholders vote to allow conversion of series D preferred shares to common shares?
0 · Reply
dmc4321
dmc4321 Feb. 20 at 5:34 PM
wow you are DUMBER THAN A ROCK. I said dont panic and attached the image showing it was an Annual Review, and then everybody else looked at my due diligence and said exactly what I said. It is all time stamped. As for $LUCD AND $PAVM I as you can read if you were not DUMBER THAN A ROCK " But if it (EsoGuard) truly is not covered and won't be covered it is just plain wrong, but LUCD will trade at 50 cents today and PAVM below $3 if it is truly NON COVERED" So to break it down into little pieces like you were a 6 year old. This is what I said. if EsoGuard is not covered that is a bad decision and is wrong. But IF CMS makes that bad decision that IMO is WRONG then the markets will react knowing that LUCD is BROKE in September and would be TWO More years MINIMUM away from approval (probably 3 to 4) by selling hard and 50 cents is probably generous. More like 30 cents. Likewise PAVM would immediaetly trade in the $2 to $3 range and soon be back in sub $1. do you understand now?
2 · Reply
dmc4321
dmc4321 Feb. 20 at 8:14 AM
$LUCD I was the ONLY poster to say 'DON'T PANIC' as all the rest of the PUMPERS were saying 'whats happening" It is all time stamped so if you think I am wrong all you have to do is show JUST ONE post from ANYONE timestamped BEFORE my 'DONT PANIC' post. You won't, because you can't.😇 As for $PAVM and $LUCD saying there is an arbitrage opportunity just shows your ignorance, STUPIDITY, and lack of accurate DUE DILIGENCE. So prove me wrong. I'll wait but I already know that i will hear 🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗🦗from you.
2 · Reply
dmc4321
dmc4321 Feb. 20 at 7:58 AM
$LUCD & $PAVM yesterday there was PANIC until I correctly laid out what happened. Today @oaksapollo posted yet ANOTHER LIE. Btw GRAL is DOWN just under 50% today. What happens if CMS considers the Grail trial which is the exact same as the 12k EsoGuard trial that is awaiting peer review and says. What should we do? Wait until the peer review process is completed or RISK issuing a draft LCD that if the 12K does not pass the peer review process we end up looking like IDIOTS, which is career suicide. Do nothing, RISK NOTHING. Do something, RISK EVERYTHING. If you had a wife and family you needed to support would you potentially commit career suicide or say lets just wait until the study has gone through the peer review process. That is the reality BTW.🥴
1 · Reply
chuckjackson
chuckjackson Feb. 19 at 9:07 PM
$LUCD pretty good day for lucd ... if it keeps going this way, you can afford to wait. Not sure what is going on with $PAVM but it has been trending down for the past week
0 · Reply
Researchpro
Researchpro Feb. 19 at 8:49 PM
$LUCD why isn’t $PAVM moving, don’t get it. At 28% of lucid stock alone they are worth above $50M . I had sold some lucid to buy pavmed after pullback on the VA contract but now its underperforming lucid.
4 · Reply
TheBearVsTheBull
TheBearVsTheBull Feb. 19 at 8:48 PM
$LUCD Dave McCarthy, You don’t understand a thing about PAVM or LUCD. Your heinous manipulation and misinformation of the stock has gone too far. The arbitrage in $PAVM maybe one of the largest opportunity I’ve seen in the Micro-Cap space in a long time. LUCD is just fine. Nothing new from MolDX. Today was an annual report that they have to do. The data is far too strong in my opinion and this test is needed everywhere.
0 · Reply
chuckjackson
chuckjackson Feb. 19 at 4:43 PM
$PAVM $LUCD You said: Are there specific examples where an annual lcd review denies coverage but soon after a draft lcd supporting coverage is issued ChatGPT said: Yes — there have been situations where an Annual LCD (Local Coverage Determination) review results in non-coverage (or continuation of non-coverage), followed relatively soon by a Draft LCD proposing coverage. While not extremely common, it does happen, typically due to new clinical evidence, stakeholder engagement, or policy reconsideration. Here are a few real-world style examples involving Medicare Administrative Contractors (MACs): 1️⃣ Pharmacogenomic (PGx) Testing • Several MACs initially issued non-coverage or limited coverage decisions for broad pharmacogenomic panels during annual LCD reviews (e.g., MolDX jurisdictions under Palmetto GBA). • After significant stakeholder pushback, submission of new clinical utility data, and alignment discussions with CMS policy trends, draft LCDs were later released proposing
1 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 3:22 PM
0 · Reply
Carter113
Carter113 Feb. 19 at 1:47 PM
$LUCD $PAVM The update from last night was just an administrative “annual review”, just like the one they did a year ago. It is not a response to the resubmission that LUCD did in November! Next week 🤞
6 · Reply
dmc4321
dmc4321 Feb. 19 at 7:43 AM
$LUCD I would NOT PANIC just yet. But if it truly is not covered and won't be covered it is just plain wrong, but LUCD will trade at 50 cents today and $PAVM below $3 if it truly is NON COVERED.
4 · Reply
Ironbow
Ironbow Feb. 19 at 12:14 AM
$LUCD $PAVM Dave ~ LPlates ~ dmc4321 ..// is such a bore now! He use to pump this stock via his Reverse psychology. Now he just lashes out like is boy, bad bunny …
0 · Reply
BigJuicy
BigJuicy Feb. 18 at 9:11 PM
$PAVM back to all time lows or break out
0 · Reply
Sunny3999
Sunny3999 Feb. 18 at 5:20 PM
0 · Reply
__ChartMenace
__ChartMenace Feb. 18 at 12:26 PM
0 · Reply